Chemical screening identifies the β-Carboline alkaloid harmine to be synergistically lethal with doxorubicin. by Atteya, R. et al.
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Despite  being  an invaluable  chemotherapeutic  agent  for several  types  of  cancer,  the  clinical  utility  of
doxorubicin  is hampered  by its age-related  and  dose-dependent  cardiotoxicity.  Co-administration  of
dexrazoxane  as a cardioprotective  agent  has  been  proposed,  however  recent  studies  suggest  that  it
attenuates  doxorubicin-induced  antitumor  activity.  Since  compounds  of  natural  origin  present  a  rich
territory for  drug  discovery,  we  set out to identify  putative  natural  compounds  with  the view  to miti-
gate or  minimize  doxorubicin  cardiotoxicity.  We  identify  the DYRK1A  kinase  inhibitor  harmine,  whicheywords:
oxorubicin
OP2
armine
ardiotoxicity
atural products
phosphorylates  Tau  that  is  deregulated  in  Alzheimer’s  disease,  as a potentiator  of  cell  death  induced  by
non-toxic  doses  of  doxorubicin.  These  observations  suggest  that  harmine  or other  compounds  that  tar-
get  the DYRK1A  kinase  my  offer  a new  therapeutic  opportunity  to suppress  doxorubicin  age-related  and
dose-dependent  cardiotoxicity.
©  2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
YRK1A kinase
. Introduction
Anthracyclines are a class of cancer chemotherapeutics con-
idered to be one of the most efﬁcacious anti-tumor drugs ever
eveloped (Minotti et al., 2004). Doxorubicin is one of the ﬁrst
nthracyclines to be discovered and is currently used clinically for
everal solid and liquid tumors (Arcamone et al., 1969). It is the ﬁrst
ine treatment for breast cancer and also used for soft tissue sar-
omas and aggressive lymphomas (Minotti et al., 2004; Carvalho
t al, 2014). The anti-tumorogenic properties of doxorubicin are
ttributed at least in part due to targeting Topoisomerase II (TOP2);
n essential cellular enzyme that is required for regulating DNA
opology during various cellular processes such as transcription,
eplication and recombination (Tewey et al., 1984; Wang 2002;
orbett and Berger, 2004; Vos et al., 2011). The mammalian genome
ncodes two isoenzymes of TOP2: TOP2 which is highly expressedPlease cite this article in press as: Atteya, R., et al., Chemical screening
lethal with doxorubicin. Mech. Ageing Dev. (2016), http://dx.doi.org/1
n rapidly dividing cells and TOP2 which resides in quiescent cells
uch as cardiac cells (Pommier et al., 2010; Vos et al., 2011). Notably,
oxorubicin possesses other TOP2-independent tumoricidal mech-
∗ Corresponding author at: Krebs Institute, University of Shefﬁeld, Shefﬁeld, S10
TN, UK.
E-mail address: s.el-khamisy@shefﬁeld.ac.uk (S.F. El-Khamisy).
ttp://dx.doi.org/10.1016/j.mad.2016.04.012
047-6374/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open acces
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
anisms such as DNA intercalation, mitochondrial targetting, and
the induction of histone eviction from open chromatin (Nitiss,
2009; Pang et al., 2013). Doxorubicin exhibits its antitumor activ-
ity primarily by targetting TOP2 in cancer cells which leads to an
increase in DNA double-stranded breaks (Tewey et al., 1984).
Nevertheless, age-related cardiotoxicity in the form of chronic
cardiomyopathy and congestive heart failure has been strongly
associated with doxorubicin treatment (Lefrak et al., 1973;
Steinherz et al., 1991; Hequet et al., 2004). Intially, doxorubicin-
associated cardiac damage was  attributed to the induction of
mitochondrial dysfunction (Wallace, 2003) and increased ROS
production in cardiac cells (Tokarska-Schlattner et al., 2006). Accu-
mulation of mitochondiral DNA damage is an established cause for
age-related degenerative diseases Doroshow, (1983); Keizer et al.,
(1990) (El-Khamisy, 2011; Akbari et al., 2015). However, a recent
study demonstrated that these effects are secondary to TOP2
isoenzyme inhibition in the heart muscle (Zhang et al., 2012).
Development of doxorubicin-induced cardiotoxicity is largely
dose-dependent (Lefrak et al., 1973), but it may  also occur at low
doses in the presence of other risk factors especially increasing age
(Von Hoff et al., 1979; Carvalho et al., 2014). It has been shown identiﬁes the -Carboline alkaloid harmine to be synergistically
0.1016/j.mad.2016.04.012
that 5%, 26% and 48% of patients developed congestive heart fail-
ure after receiving cumulative doses of 400 mg/m2, 550 mg/m2 and
700 mg/m2 of doxorubicin respectively (Swain et al., 2003). Several
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Tig. 1. Determination of the cytotoxicity of natural compounds on the breast cancer
nd  100 M for 48 h followed by the determination of cell viability using the CellTi
s  a percentage relative to that of a DMSO control.
tudies pointed towards age being one of the most signiﬁcant risk
actors in developing doxorubicin-mediated cardiac damage with
hildren and elderly patients being the most suceptible to develop-
ng this side effect (Von Hoff et al., 1979; Kremer et al., 2002; Swain
t al., 2003; Doyle et al., 2005; Lipshultz, 2006). For elderly patients,
educed doxorubicin clearance caused by a decline in the regional
lood ﬂow may  be the primary reason for their increased suscep-
ibility to cardiotoxicity (Robert and Hoerni, 1983; Li and Gwilt,
003). Interestingly, postmortem analysis of patients treated with
oxorubicin exhibited high accumulation of the drug in the cardiac
uscle (Hong et al., 2002).
One proposed strategy to minimize this deleterious side effect is
he co-administration of dexrazoxane, an FDA-approved cardiopro-
ective agent (Speyer et al., 1988; Speyer et al., 1992). Dexrazoxane
cts by complexing the TOP2 ATPase domain and thus block-
ng doxorubicin binding to the cardiac TOP2. However, the ATPase
omain is identical in both TOP2 and TOP2 which means that
exrazoxane administration could diminish doxorubicin’s tumori-
idal activity (Lyu et al., 2007; Vejpongsa and Yeh, 2014). Moreover,
tudies regarding the combined anticancer activity of doxorubicin
nd dexrazoxane have reported contradictory results (Wadler et al.,
986; Hasinoff et al., 1996; Pearlman et al., 2003). The problem
f doxorubicin-induced cardiotoxicity still poses a serious unmet
hallenge limiting its clinical utility.
Natural products have been historically the most rich source ofPlease cite this article in press as: Atteya, R., et al., Chemical screening
lethal with doxorubicin. Mech. Ageing Dev. (2016), http://dx.doi.org/1
rug leads owing to the fact that they exhibit unparalleled struc-
ural diversity compared to combinatorial chemistry (Mishra and
iwari, 2011; Dias et al., 2012). Indeed, nature presents an untappedine, MCF-7. MCF-7 cells were treated with the indicated compounds at 0.1, 1, 10, 50
ue®Cell Viability Assay (Promega). Viability at a given concentration is determined
reservoir of chemical structures with potential biological activities
(Dixon, 2001). Plant extracts such as that of Taxus baccata (Euro-
pean yew) tree and Catharanthus roseus,  also known as Vinca rosea,
were found to exhibit cytotoxic effects (Mantle et al., 2000). Cur-
rent regimens for the treatment of breast cancer also include that of
vinblastine, another indole alkaloid from vinca plant and a known
component of a number of chemotherapies (Ospovat et al., 2009).
The hunt for other potential cytotixic drug entities from natural
origin will continue to grow. In the current study, we  aimed to
identify a synthetic lethal interaction between doxorubicin and a
natural product using the breast cancer cell line MCF-7 with the
view to obtain preliminary evidence to supress cardiotoxicity. For
this purpose, compounds from a library of natural product isolates
derived mostly from plant origin were assessed in combination
with doxorubicin at sub-toxic concentrations. We  identify harmine,
a -carboline alkaloid, to be synergistically toxic in short-term via-
bility assays and additively toxic in long-term clonogenic survival
assays, with doxorubicin. We  propose that co-adminisstration of
harmine and doxorubicin will permit the use of lower doses of the
latter and thus help reduce its associated dose-dependent cardiac
damage.
2. Materials and methods identiﬁes the -Carboline alkaloid harmine to be synergistically
0.1016/j.mad.2016.04.012
2.1. Chemicals
Caffeic acid, p-coumaric acid, naringinen, chlorogenic acid,
quercetin, isoquercetin, umbelliferone, harmine, luteolin, caf-
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Table  1
Summary of the natural compounds used in the study.
Compound Name CAS Number Class Sub-lethal Concentration (M)
1 Caffeic acid 331-39-5 Phenolic acid 100
2  Khellin 82-02-0 Chromone 10
3  p-Coumaric acid 7400-08-0 Phenolic acid 100
4  Naringenin-7-O-glycoside 529-55-5 Flavonoid 10
5  Allyl anthranilate 7493-63-2 Terpenoid 0.1
6  Cynarin 1182-34-9 Phenolic acid 0.1
7  Caffeine 58-08-2 Alkaloid 10
8  Isoquercitrin 482-35-9 Flavonoid 10
9  Umbelliferone 93-35-6 Coumarin 0.1
10  2,4,4′ trihydroxy chalcone 961-29-5 Flavonoid 0.1
11  Emodin 518-82-1 Aanthraquinone 10
12  Chrysin 480-40-0 Flavonoid 10
13  Sennoside A 81-27-6 Aanthraquinone 50
14  Isoeugenol 97-54-1 Phenylpropanoid 100
15  Pseudoephedrine 90-82-4 Alkaloid 100
16  Glycyrrhizin 1405-86-3 Saponin 100
17  Epicatechin 490-46-0 Flavonoid 50
18  Rutin 153-18-4 Flavonoid 100
19  Vanillic Acid 121-33-5 Phenylpropanoid 100
20  Gallic acid 149-91-7 Phenolic acid 10
21  Xanthohumol 6754-58-1 Flavonoid 1
22  Beta-glycyrrhetinic acid 471-53-4 Terpenoid 100
23  Naringenin 67604-48-2 Flavanoid 100
24  Harmine 442-51-3 Alkaloid 0.1
25  Luteolin 491-70-3 Flavooid 50
26  Kaempferol 520-18-3 Flavonoid 50
27  Hesperidin 520-26-3 Flavonoid 100
28  Bisabolene 17627-44-0 Terpenoid 100
29  Alpha-ionone 127-41-3 Terpenoid 100
30  z-3-Hexenyl acetate 3681-71-8 Terpenoid 0.1
31  Alpha-Pinene 80-56-8 Terpenoid 100
32  Cuminaldehyde 122-03-2 Phenylpropanoid 100
33  Thymol 89-83-8 Phenylpropanoid 100
34  Caryophyllene oxide 17627-43-9 Terpenoid 10
35  Carvone 99-49-0 Terpenoid 0.1
36  Methyl Disulphide 624-92-0 Sulphur compound 10
37  Amentoﬂavone 1617-53-4 Flavonoid 50
38  Sarcophine 55038-27-2 Terpenoid 50
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a39  Chlorogenic acid 327-97-9 
40  Vitexin 3681-93-4
41  Quercetin 117-39-5 
eine, 2,4,4′-trihydroxy chalcone, naringinin-7-glucoside, pseu-
oephedrine, glycyrrhizin, epicatechin, vanillic acid, gallic acid,
-glycyrrhetenic acid, xanthohumol and amentoﬂavone were pur-
hased from Sigma Aldrich (St. Louis, MO,  USA). Bisabolene,
-ionone, (Z)-3-hexenyl acetate, allyl anthranilate, isoeugenol,
-pinene, cuminaldehyde, thymol, caryophyllene oxide, carvone
nd methyl disulphide were provided from Bedoukian Research
Danbury, CT USA). Cynarin, emodin, rutin and sennoside A were
urchased from Chromadex (Wesel, Germany). Khellin was  a
ift from Prof. Dieter Treutter (Tech Univ. of Munich, Germany).
arcophine was isolated from Sarcophyton ehrenbergi soft coral
hereas vitexin and chrysin were isolated from Passiﬂora edulis
eaf in Dr. Farag laboratory, Cairo University. All compounds were
issolved in Dimethyl sulfoxide (DMSO).
.2. Cell culture
Michigan Cancer Foundation (MCF-7) cells were obtained from
r. El-Khamisy’s laboratory at the University of Shefﬁeld, UK and
ultured in DMEM media (Lonza) supplemented with 10% Fetal
ovine Serum (Gibco), 100 units of Penicillin/Streptomycin (Lonza)
nd 100 U/ml L-Glutamine (Lonza) at 37 ◦C and 5% CO2.Please cite this article in press as: Atteya, R., et al., Chemical screening
lethal with doxorubicin. Mech. Ageing Dev. (2016), http://dx.doi.org/1
.3. Cell viability assays
MCF-7 cells were plated at a density of 5000 cells in triplicates in
 96-well plate. Next day, cells were treated with the indicated com-Phenolic acid 10
Flavonoid 1
Flavonoid 50
pounds (Table 1) at the indicated concentrations in a ﬁnal volume
of 100 l. Cell viability was assessed after 48 h using CellTiter-
Blue®Cell Viability Assay (Promega). 20 ls of the reagent were
added to each well, the plate was  incubated for 3 h and ﬂuores-
cence was subsequently measured (490 nm)  using a plate reader.
The viability was  calculated relative to a DMSO control.
2.4. Clonogenic assay
MCF-7 cells were plated at a density of 2000 cells in 10-cm dishes
followed by treatment with the indicated compounds (Table 1) on
the next day. After 12 days, colonies were ﬁxed, stained with 1%
Giemsa Stain in Methanol and the colonies containing more than
50 cells were counted and the survival was calculated relative to
counts in DMSO controls.
3. Results
3.1. Synthetic lethal screen of natural compounds with
doxorubicin using the breast cancer cell line MCF-7
We assembled a library of forty-one natural products of plant
origin belonging to various chemical classes including alkaloids identiﬁes the -Carboline alkaloid harmine to be synergistically
0.1016/j.mad.2016.04.012
viz. harmine, phenylpropanoids viz. isoeugenol, terpenoids viz.
caryophyllene oxide & sarcophine, ﬂavonoids viz. xanthohumol,
anthraquinones viz. sennossoide A, saponins viz. glycyrrhizin and
phenolic acids viz. gallic acid (Suppl. Fig. 1). We ﬁrst assessed
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Fig. 2. Synthetic viability screen of natural compounds and doxorubicin on MCF-7. MCF-7 cells were treated with the indicated natural compounds at their sub-toxic
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concentration (Table 1) in combination with doxorubicin at 0.1, 0.3, 0.5 and 1 M.
reatments were performed for 48 h followed by the determination of cell viability u
s  determined as a percentage relative to that of a DMSO control.
he toxicity of the natural compounds on MCF-7 cells by mea-
uring their viability following treatment at ﬁve doses spanning
rom 0.1 to 100 M (Fig. 1A–E). The sub-toxic concentration for
ach compound was determined, which we deﬁned as the con-
entration which could incur less than 15% cytotoxicity (Table 1).
he established IC values or sub-toxic doses were used as the
ependent variables in the cluster analysis to determine similar-
ties in the cytotoxic activity of the tested compounds. Hierarchical
luster analysis identiﬁed four distinct groups based on the level
f their cytotoxic activity against MCF-7 cell line (Suppl. Fig.
). The groups obtained were: (1a) Pseudoephedrine, naringi-
en, hesperidin, rutin, caffeic acid, p-coumaric acid, vanillic acid,
isabolene, -ionone, isoeugenol, -pinene, cuminaldehyde, thy-
ol, -glycyrrhetenic acid and glycyrrhizin with an IC value of
00 M;  (1b) Sennoside A, kaempferol, quercetin, epicatechin,
uteolin, amentoﬂavone, sarcophine, caffeine, emodin, khellin,
soquercetrin, chrysin, chlorogenic acid, gallic acid, naringinin-7-
-glucoside, caryophyllen oxide and methyl disulphide with an
C value of 10–50 M;  (1c)  Umbelliferone, 2,4,4′-trihydroxy chal-
one, cynarin, (Z)-3-hexenyl acetate, allyl-anthranilate, carvone,
armine, xanthohumol and vitexin with an IC value of 0.1–1 M
nd being most active among all examined chemicals. It should be
oted that no segregation of compounds could be observed based
n its class group i.e. alkaloids, ﬂavonoids etc. Among the examined
ompounds, we observed that harmine, luteolin, 2,4,4-trihydroxy
halcone, gallic acid and xanthohumol exhibited the highest cyto-Please cite this article in press as: Atteya, R., et al., Chemical screening
lethal with doxorubicin. Mech. Ageing Dev. (2016), http://dx.doi.org/1
oxicity on MCF-7 cells. This is in line with the reported effect of
he dietary ﬂavonoids luteolin (Sato et al., 2015) and xanthohumol
Blanquer-Rossello et al., 2013) on the MCF-7 human breast cancer
ell line. Next, we performed the subsequent screen where we com-rubicin was  determined to be non-toxic to MCF-7 cells at 0.1, 0.3 and 0.5 M.  The
he CellTiter-Blue®Cell Viability Assay (Promega). Viability at a given concentration
bined the compunds at their sub-lethal concentration (Table 1) with
four concentrations of doxorubicin: three of which were sub-lethal
(0.1, 0.3 and 0.5 M)  and one was  lethal (1 M)  (Fig. 2A–E). How-
ever, this screening scheme failed to yield a combination which
could result in a signiﬁcant synergistic cytotoxic effect. We  rea-
soned that it may  have been due to an inherent short outcome in the
viability assay or the concentrations used of both agents were not
optimal to produce detectable synergism. Thus, we  decided to re-
examine the top ﬁve compounds observed in the primary screen to
display the strongest cytotoxic effect on MCF-7 cells but now with
the additional presence of varying concentrations of doxorubicin.
3.2. The ˇ-carboline alkaloid harmine potentiates
doxorubicin-induced cytotoxicity on MCF-7 cells
We  examined the effect of the compounds at varying concen-
trations alone or in combination with two ﬁxed concentrations of
doxorubicin (0.5 and 1 M)  on MCF-7 cell viability. Out  of the ﬁve
compounds, harmine demonstrated a dose-dependent cytotoxic-
ity on MCF-7 cells (Fig. 3A) and the most potent inhibition of cell
viability when combined with doxorubicin (Fig. 3B). It should be
noted that such synergism appeared at low doses of both agents
(1 M for harmine and 0.5 M for doxorubicin). Harmine was pre-
viously found to exhibit cytotoxic effects though used at much
higher concentrations ranging from 10 to 50 M (Ma  and Wink,
2010; Dai et al., 2012; Zhao and Wink, 2013). Interestingly, lute- identiﬁes the -Carboline alkaloid harmine to be synergistically
0.1016/j.mad.2016.04.012
olin identiﬁed among the 5 structural hits is known to attenuate
doxorubicin-induced cytotoxicity to MCF-7 cells (Sato et al., 2015)
and that could account for the lack of a synergistic effect with dox-
orubicin in this study. To further conﬁrm the observed synergism,
ARTICLE IN PRESSG ModelMAD-10848; No. of Pages 8
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Fig. 3. Harmine potentiates doxorubicin-induced cytotoxicity in MCF-7 cells. (A) Viability of MCF-7 cells following treatment with the indicated concentrations of Harmine.
(B)  MCF-7 cells were treated with the indicated concentrations of harmine alone or in combination with 0.5 or 1 M doxorubicin. (C) MCF-7 cells were treated with different
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toncentrations of doxorubicin with or without 1 M of harmine. In all assays, treat
ellTiter-Blue®Cell Viability Assay (Promega). Viability at a given concentration is 
rom  three independent biological replicates. Asterisks denote statistical signiﬁcanc
CF-7 cells were treated with increasing doses of doxorubicin in
he absence or presence of 1 M harmine and evaluated for cell
iability (Fig. 3C).
.3. Harmine does not exhibit cytotoxic synergism with other
opoisomerase poisons
Considering that both harmine and doxorubicin displayed cell
illing effects on MCF-7 cells, we wondered whether similar effects
ould occur with other topoisomerases poisons widely used in the
linic (Gilbert et al., 2012; Alagoz et al., 2012). MCF-7 cells were
reated with the TOP1-poison camptothecin (Fig. 4A) or with the
OP2-poison etoposide (Fig. 4B) in the absence or presence of 1 M
armine, and assessed for cell viability. The addition of harmine did
ot enhance the cytotoxicity of either poison, suggesting that the
bserved synergistic effect is speciﬁc to doxorubicin.
.4. Harmine and doxorubicin inhibit MCF-7 survival as
easured by colony formation assays
The clonogenic survival assay determines the ability of single
ells to form a colony where a colony is formed of at least ca.  50 cells.Please cite this article in press as: Atteya, R., et al., Chemical screening
lethal with doxorubicin. Mech. Ageing Dev. (2016), http://dx.doi.org/1
his assay measures the ability of every cell to undergo limitless
ivision and is considered to be a more accurate readout for cyto-
oxicity, providing more insight on the long-term effects of a certain
reatment compared to cell viability assays (Franken et al., 2006). were performed for 48 h followed by the determination of cell viability using the
ined as a percentage relative to that of a DMSO control. Data are the mean ± s.d.
< 0.05 and **P < 0.01 by student t-test).
We  determined the ability of MCF-7 to form colonies after 12-day
treatments of different concentrations of harmine with or without
10 nM doxorubicin (Fig. 4C). Harmine on its own  reduced MCF-7
colony formation ability by ca. 35% at a concentration of 800 nM
and the additional presence of doxorubicin further reduced colony
formation in an additive manner. Notably, harmine was identiﬁed
as a high afﬁnity inhibitor of DYRK1A, a kinase that phosphory-
lates the tau protein, which is deregulated in Alzheimer’s disease
(Gockler et al., 2009; Frost et al., 2011). We  therefore examined
whether other reported DYRK1A inhibitors would simillarly poten-
tiate the cytotoxic effect of doxorubicin on MCF-7 cells. Consistent
with this notion, the DYRK1 inhibitor INDY exhibited a simillar but
milder additive cytotoxic effect with doxorubicin, suggesting that
inhibiting DYRK1 kinase may  provide a plausible mechanism for
the observations reported in this study (Fig. 4D).
4. Discussion
Antineoplastic agents with varying degree of efﬁcacy and
accompanying side effects target several cancer-driving signal-
ing pathways. Topoisomerases types IIA (TOP2 and TOP2) are
elegant enzymes which resolve DNA topological entanglements identiﬁes the -Carboline alkaloid harmine to be synergistically
0.1016/j.mad.2016.04.012
during several cellular processes and are the molecular targets of
the commonly used and one of the most effective antineoplas-
tic agents; doxorubicin (Ashour et al., 2015). Despite being one
of the most efﬁcacious anticancer drugs (Weiss, 1992), it is well
ARTICLE IN PRESSG ModelMAD-10848; No. of Pages 8
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Fig. 4. Harmine does not enhance the cytotoxic effect of camptothecin or etoposide cells but potentiates the cytotoxic effect of doxorubicin as measured by clonogenic survival
assays. MCF-7 cells are treated with increasing concentration of camptothecin (A) or etoposide (B) with or without 1 M Harmine for 48 h and assessed for cell viability using
C  conce
o C) or I
C al wa
e
c
w
H
a
u
i
o
d
c
S
I
s
2
e
e
w
d
1
u
oellTiter-Blue®Cell Viability Assay (Promega). Percentage of cell viability at a given
f  three independent experiments. MCF-7 cells were treated with either Harmine (
ells  were assessed for their ability to form macroscopic colonies Percentage surviv
stablished that doxorubicin causes chronic cardiomyopathy and
ongestive heart failure related to the cumulative dose of the drug
here each dose adds an incremental injury to the heart (Von
off et al., 1979; Swain et al., 2003; Wouters et al., 2005; Yeh
nd Bickford, 2009; Vejpongsa and Yeh, 2014). Several risk factors
nderpin the probability of developing cardiac damage follow-
ng doxorubicin treatment but notably, age was found to be one
f the most signiﬁcant among them. Doxorubicin-associated car-
iotoxicity has been observed to be more frequent in older patients
ompared to their younger counterparts (Von Hoff et al., 1979;
wain et al., 2003; Hequet et al., 2004; Hershman et al., 2008).
nterestingly, cardiac damage was found to increase with age. A
tudy of the long-term effects of anthracycline chemotherapy on
01 patients showed that 23% of the cohort developed cardiac side
ffects up to 10 years after the cessation of treatment (Steinherz
t al., 1991). Another study showed that pediatric cancer patients
ho received anthracycline treatment had a high incidence of
eveloping cardiotoxicity later in life (Steinherz and Steinherz,Please cite this article in press as: Atteya, R., et al., Chemical screening
lethal with doxorubicin. Mech. Ageing Dev. (2016), http://dx.doi.org/1
991). The cause behind this long-term cardiotoxicity is not well
nderstood. This serious side effect has signiﬁcant impact on the
verall prognosis and survival of cancer patients.ntration is determined relative to a DMSO control. Data represents the mean ± s.d.
NDY (D) alone or in combination with 10 nM doxorubicin continuously for 12 days.
s  calculated from three biological replicated and presented as the average ± s.d.
Such serious side effects warrant the hunt for novel interven-
tions that can help prevent anthracycline-induced cardiotoxicity.
Anticancer drug research in the last 20 years has utilized novel
strategies to identify cancer-speciﬁc traits that can be exploited
for selective targeting. One promising strategy is synthetic lethal
screens, which is based on the interaction of two or more genes
that contribute to the same vital process (Chan and Giaccia, 2011).
Here, we hypothesized that cancer killing efﬁciency of doxorubicin
could be achieved by sub-lethal non-toxic doses if combined with
novel compounds targeting previously unidentiﬁed genetic path-
ways. In a hunt for such compounds we performed a synthetic lethal
screen using doxorubicin and a library of natural products of plant
origin. Naturally derived drugs appear more rewarding than syn-
thetic agents since they are less likely to display toxic side effects.
Our screen revealed the -carboline alkaloid harmine as a putative
potentiator of doxorubicin cytotoxicity.
Harmine is isolated from several medicinal plants including
Peganum harmala and Passiﬂora edulis.  It has been reported to identiﬁes the -Carboline alkaloid harmine to be synergistically
0.1016/j.mad.2016.04.012
exhibit anti-viral (Hudson et al., 1986), anti-leishmanial (Lala et al.,
2004) and anti-neoplastic activities (Hamsa and Kuttan, 2010).
Furthermore, recently, its anti-diabetic effect via the induction of
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ancreatic beta-cell proliferation holds promise for its use in dia-
etes therapy (Wang et al., 2015). Herein, we identify a novel
unction of harmine as a potentiator of doxorubicin cytotoxicity
n the breast cancer cell line MCF-7. This combination even at
ow doses reduces cell viability compared to that of either agent
lone (Figs. 3 B, 4 C). The mechanism by which harmine exerts
ts potentiating effect with doxorubicin could be due to improv-
ng doxorubicin reported inhibitory effect on TOP2. It could also be
ttributed to the reported effect of harmine as a DYRK1A kinase
nhibitor, which may  modulate mitochondrial function and the
ynamics of reactive oxygen species. We  favor the latter possi-
ility for two reasons. First, harmine did not display detectable
ynergistic or additive activity with etoposide, a speciﬁc TOP2 poi-
on. Second, the DYRK1 kinase inhibitor INDY similarly displayed
dditive cytotoxicity with doxorubicin in colony formation assays
Fig. 4C and D).
Further studies are required to determine the anti-cancer effect
f the combination proposed here, in other breast cancer cell lines
nd in xenograft mouse models. Importantly, follow-up studies
ill compare the cardiotoxicity of doxorubicin alone and with
he additional presence of harmine, which is predicted to permit
he use of lower non-, or less, cardiotoxic doses of doxorubicin.
nalyzing biological structure-activity relationships among other
tructurally related -carboline alkaloids, e.g. harmane, may  iden-
ify more potent synergism with doxorubucin. Similarly, assessing
ther DYRK1 inhibitors for their combined effects with doxorubicin
ay  present a worthwhile investigation. These studies could serve
s a guide for the rational design of further antitumor drugs and
o help identifying structural motifs crucial for cytotoxic activity,
ith the view to minimize cardiotoxicity.
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